FDA Central Review Likely For Novel Surrogate Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.
You may also be interested in...
PDUFA VII Could Expand US Real-Time Review Beyond Oncology
A proposed pilot program would offer for “split submission and review” of some application sections in other disease areas. Discussions also touch on concept of a CDER-CBER RWE committee.
US FDA Hoping To Solve Drug-Software Issues With Digital Health Working Group
As more applications include software components, group wants assessors to apply best practices from CDRH to CDER whenever possible.
PDUFA Budgeting: What Will Get Added, Subtracted – Or Multiplied By Cures?
Industry official sees potential for some streamlining in user fee program, but adding to breakthrough and patient-centered activities seems most likely.